Les cellules ciliées sont les cellules sensorielles de la cochlée, l’organe de l’audition, et assurent la transduction des stimulations acoustiques en message nerveux compréhensible par le système nerveux central. Nous avons étudié le rôle du cytosquelette dans le transfert synaptique et dans le cadre d’une neuropathie auditive.La première partie de cette thèse a consisté à déterminer le rôle des filaments d’actine dans l’exocytose des cellules ciliées. Pour ce faire, nous avons infusé des toxines connues pour dépolymériser les filaments d’actine directement dans les cellules ciliées internes. Après 10 minutes d’infusion, nous avons mesuré l’exocytose des cellules ciliées à partir de l’enregistrement de la capacité membranaire, indice de la fusion vésiculaire. Dans nos expériences, la dépolymérisation de l’actine provoquait une augmentation de l’exocytose. De plus nos résultats suggèrent qu’une fraction des vésicules éloignées des canaux calciques se rapproche des sites de libération après dépolymérisation du réseau d’actine. Ces travaux ont donc permis d’identifier une sous-population de vésicules synaptiques dont la disponibilité aux sites de fusion est dépendante des filaments d’actine. La seconde partie de cette thèse porte sur les mécanismes à l’origine d’une neuropathie auditive, la surdité AUNA1. Cette dernière se caractérise par la surexpression cytoplasmique de la protéine Diaph3, dont la fonction est de réguler la nucléation de l'actine et des microtubules. Pour étudier AUNA1, nous avons montré que les souris transgéniques qui surexpriment la protéine Diap3 (protéine murine) développent une surdité progressive, similaire à la neuropathie auditive AUNA1 : soit une élévation des seuils auditifs et des otoémissions normales, témoins de l’activité des cellules ciliées externes (qui ont pour rôle d’amplifier les stimulations sonores). En outre, le potentiel de sommation, qui reflète l’activité in vivo des cellules ciliées internes est altéré chez les souris transgéniques. L’observation des cellules ciliées internes en microscopie électronique à balayage montre un gonflement de la plaque cuticulaire, qui est une plateforme dense en actine servant à ancrer les stétéocils. L’observation en microscopie confocale du réseau de microtubules montre que ce dernier entoure la plaque cuticulaire chez les souris sauvages. A l’inverse, les microtubules envahissent la plaque cuticulaire chez les souris transgéniques. L’ensemble de ces résultats a donc permis de montrer un défaut d’adressage des microtubules à l’origine de la surdité AUNA1. / Inner hair cells transduce sound stimulation into neurotransmitter release onto the afferent auditory nerve fibers. Here, we studied how cytoskeleton modulates the transduction capabilities of the inner hair cells. Exocytosis at the inner hair cell ribbon synapse is achieved through the coupling between calcium channels and glutamate-filled synaptic vesicles. Using membrane capacitance measurements, we probed whether the actin filament network regulates the exocytosis of synaptic vesicles at the auditory hair cell. Our results suggest that actin network disruption increases exocytosis and that actin filaments may spatially organize a sub-fraction of synaptic vesicles with respect to the calcium channel.The auditory neuropathy 1 (AUNA1) is a form of human deafness, which results from a point mutation in the 5’untranslated region of the Diaphanous homolog 3 (DIAPH3) gene. Strikingly, the DIAPH3 mutation leads to the overexpression of the Diaph3 protein, a formin family member involved in the cytoskeleton nucleation and stabilization. Here, we examined in further details the anatomical, functional and molecular mechanisms that account for AUNA1. We found out that the Diap3-overexpressing transgenic mice show a progressive threshold shift associated to a defect in the inner hair cells. While synaptic function was not affected, Diap3-overexpression results into a selective and early-onset alteration of the inner hair cells cuticular plate, a dense plateform anchoring the stereocilia bundle. Molecular dissection of the apical components revealed that the microtubule meshwork undergoes an aberrant targeting into the cuticular plate of the transgenics’ inner hair cells at early onset, leading to the inabilities of these sensory cells to transduce incoming sound stimulation at later stages.

Volatile substances such as perfumes, insect pheromones and volatile corrosion inhibitors can be released into the atmosphere from polymer matrices. The release characteristics of the volatile substances depend on the original concentration of the substances, and also on the type and geometry of the matrix. The design of the matrix can be done with a trial and error process involving several iterations of tool making followed by testing of the release characteristics. However, this is a costly and time-consuming method. The objective of this study is to propose and evaluate a mathematical model based on Fick's second law of diffusion. The model can be used to predict the release profiles of volatile substances from polymer matrices based on the initial volatile concentration, matrix geometry and the coefficient of diffusion of the volatile through the polymer. The alcohols I-propanol, I-butanol, I-hexanol and I-octanol and the polymer ethylene-eo-vinyl acetate (EVA) were chosen as a model system for this study. The coefficients of diffusion of all the alcohols through the EVA were determined with the time lag test using a diffusion cell and polymer sheets. Several methods of making polymer sheets were evaluated. Injection moulded disks was the most suitable method for the system under consideration. Based on the results of the time lag tests, the proposed model was used to predict the release characteristics of the different alcohols from two EVA matrix designs. Injection moulded test pieces of both designs were prepared. All the test pieces contained ca. 10% of one of the alcohols. The test pieces were aged at ambient conditions and the release of the alcohols was monitored. It was found that the proposed model gave a good prediction of the residual mass of the dispensers, never diverging more than 10% from the experimental result. The experimental results tended to show faster release than predicted. This was expected since the model does not consider the effect of concentration on the coefficient of diffusion. It was concluded that the model gave accurate predictions of the release characteristics of the system investigated. It would be a useful tool in the design and development of polymer dispensers for volatile substances. The smaller number of tool modifications and release tests required will lead to cost and time savings in the development process. / Dissertation (M Eng (Chemical Engineering))--University of Pretoria, 2006. / Chemical Engineering / unrestricted

Carbamazepine (CBZ) is a first-line drug used for the treatment of partial and tonic-clonic seizures. It is also the drug of choice for use during pregnancy and recommended for the treatment of seizure disorders in children. CBZ possesses the ability to induce metabolism of drugs that are transformed in the liver and has the unique ability to induce its own metabolism by a phenomenon known as ‘auto- induction’, where its biological half-life is significantly reduced during chronic administration. Large doses of CBZ are often prescribed as daily divided doses and this often adversely affects patient compliance, with the result that therapy is ineffective. A sustained-release dosage form containing CBZ is currently marketed as Tegretol® CR and the development of a generic product would provide patients with an equivalent product with a similar dosing frequency, at a reduced cost. Therefore, the development of a polymer-based matrix tablet was undertaken to produce a sustained-release dosage form of CBZ, since these dosage forms are relatively simple and cheap to produce when compared to other, more sophisticated forms of sustained-release technology. Preformulation studies were conducted to assess moisture content of excipients and dosage forms and to identify possible incompatibilities between CBZ and potential formulation excipients. Furthermore, studies were conducted to assess the potential for polymorphic transitions to occur during manufacture. Stability testing was conducted to assess the behaviour of the dosage forms under storage conditions that the product may be exposed to. Dissolution testing was undertaken using USP Apparatus 3, which allowed for a more realistic assessment and prediction of in vivo drug release rates. Samples were analysed using a high performance liquid chromatographic method that was developed and validated for the determination of CBZ. Tablets were manufactured by wet granulation and direct compression techniques, and the resultant drug release profiles were evaluated statistically by means of the f1 and f2 difference and similarity factors. The f2 factor was incorporated as an assessment criterion in the design of an artificial neural network that was used to predict drug release profiles and formulation composition. A direct compression tablet formulation was successfully adapted from a prototype wet granulation matrix formulation and a number of formulation variables were assessed to establish their effect(s) on the dissolution rate profile of CBZ that resulted from testing of the dosage forms. The particle size grade of CBZ was also investigated and it was ascertained that fine particle size grade CBZ showed improved drug release profiles when compared to the coarse grade CBZ which was desirable, since CBZ is a highly water insoluble compound. Furthermore, the impact of the viscosity grade and proportion of rate-controlling polymer, viz., hydroxypropyl methylcellulose was also investigated for its effect on drug release rates. The lower viscosity grade was found to be more appropriate for use with CBZ. The type of anti-frictional agent used in the formulations did not appear to affect drug release from the polymeric matrix tablets, however specific compounds may have an effect on the physical characteristics of the polymeric tablets. The resultant formulations did not display zero-order drug release kinetics and a first-order mathematical model was developed to provide an additional resource for athematical analysis of dissolution profiles. An artificial neural network was designed, developed and applied to predict dissolution rate profiles for formulation. Furthermore, the network was used to predict formulation compositions that would produce drug release profiles comparable to the reference product, Tegretol® CR. The formulation composition predicted by the network to match the dissolution profile of the innovator product was manufactured and tested in vitro. The formulation was further manipulated, empirically, so as to match the in vitro dissolution rate profile of Tegretol® CR, more completely. The test tablets that were produced were tested in two health male volunteers using Tegretol® CR 400mg as the reference product. The batch used for this “proof of concept” biostudy was produced in accordance with cGMP guidelines and the protocol in accordance with ICH guidelines. The test matrix tablets revealed in vivo bioavailability profiles for CBZ, however, bioequivalence between the test and reference product could not be established. It can be concluded that the polymeric matrix CBZ tablets have the potential to be used as a twice-daily dosage form for the treatment of relevant seizure disorders.

Conventional solid dosage forms often lead to fluctuations which exceed the maximum safe therapeutic level and/or decline below the minimum effective level. It is recognised that many drugs for chronic administration should be administered on a schedule that maintains plasma drug concentration within the therapeutic window. Research in controlled release dosage forms aims at designing a system with a zero-order input (eg, ideally to deliver 8.33% of the dose per hour over a 12 hour duration), producing steady state plasma drug levels. Oral dministration of drugs prepared as a controlled release formulation is extremely popular, and has attracted the attention of pharmaceutical scientists during the last decade. This has been due to the simultaneous convergence of various factors (eg, discovery of novel polymers and devices, better understanding of formulation and physiological constraints, expiration of existing patents, prohibitive cost of developing new drug entities), involved in the development of these delivery systems. Controlled release oral products can be formulated as single or multiple unit dosage forms and the relative merits of multiple unit forms with their own rate controlling systems are well established. This work describes the development of a relatively inexpensive multiple-unit capsule dosage form of theophylline containing coated mini-tablets for drug delivery throughout the gastrointestinal tract. Preformulation studies on theophylline anhydrous included solubility and dissolution rate determinations. Techniques including X-ray powder diffraction, differential scanning colorimetry and infrared spectroscopy provided no evidence of true polymorphism after recrystallisation from various solvents. However, scanning electron micrographs showed the effects of solvent polarity and cooling rate on the size and shape of recrystallised particles. Theophylline granules were manufactured by using various binders and were film coated by fluidised bed technology with various proportions of ethylcellulose, containing varying amounts of PEG 1540. In vitro release rates were dependent upon coating thickness and the proportion of PEG, which, being water soluble, created pores in the coating during dissolution studies as observed by a scanning electron microscope. However, substantial proportions of the drug remained unreleased from the granules. In order to overcome the problems of drug retention, plain granules were used and theophylline mini-tablets (3 mm diameter, weighing 15 - 20 mg) were manufactured and film coated with various Eudragits ® and other polymeric mixtures (soluble and insoluble). In vitro dissolution profiles from samples enclosed in hard gelatin capsules were determined using the USPXXI paddle apparatus in test media at pH 1.2 (HCI), pH 5.4 and 7.4 (phosphate buffers) at 37'C. Monitoring of in vitro theophylline release over 12 h, under identical hydrodynamic conditions, showed that the dissolution rate at pH 1.2 is substantially greater (95% of total drug content released in < 10 h) than that in phosphate buffers. The maximum release after 12 h was approximately 20 and 30% of total drug content of the tablet at pH 5.4 and 7.4, respectively. However, in vivo bioavailability after oral administration of tablets to rabbits corresponded to over 95% of total drug, compared with the same dose administered intravenously. The retarded drug release during in vitro dissolution in phosphate buffer was attributed to a possible interaction of phosphate ions with theophylline molecules at the tablet core-coat interface. These findings indicate that both rate and extent of theophylline release from the slow release coated mini-tablets are highly sensitive to phosphate buffers. The data also emphasise the usefulness of an animal model for assessment of in vivo drug release and subsequent absorption during the development of modified release dosage forms. Mini-tablets were subjected to isothermal and cyclic stresses to reach conditions for up to 6 months at different temperatures and relative humidity. The film integrity was maintained but ageing of the coating occurred which impeded dissolution. Reduced drug release was temperature related while the effect of relative humidi% was insignific~t. Encapsulated mini-tablets (uncoated and coated with Eudragit RL and RS 2% w/w) equivalent to a 300 mg dose, were evaluated both in vitro and in vivo using beagle dogs. The pharmacokinetic parameters from single and multiple dose studies showed several advantages over Theo-Dur® 300 mg tablets. Precise dosage titration is possible by careful adjustment of the number of encapsulated mini-tablets. This multiple unit mini-tablet delivery system will allow for greater flexibility in dosage adjustment compared to the currently available preparations, allowing individualised fine dose titration in those patients requiring therapeutic drug monitoring. The developmentof the multiple unit mini-tablet formulation appears to provide an optimal dosage form with maximum flexibility in respect of dose, duration range and ease of production.

Contexte : Le démasquage binaural est un processus indispensable pour la compréhension en environnement bruyant. Ce mécanisme ferait intervenir la comparaison d’indices temporels et fréquentiels tout au long des voies nerveuses auditives. Cependant, il n’existe pas de réel consensus évoquant un traitement du démasquage à un niveau sous-cortical et/ou cortical. L’objet de cette étude est d’étudier ces indices temporels et fréquentiels du démasquage par le biais d’une étude perceptive, puis d’une étude électroencéphalographique (EEG). Matériels et méthodes : Une population normoentendante a été évaluée lors d’une étude perceptive visant à estimer l’importance du démasquage en fonction de 1) la largeur fréquentielle du bruit controlatéral (de 1 octave, 3 octaves ou à large bande), 2) la cohérence temporelle des bruits bilatéraux (corrélation égale à 0 ou 1) et 3) la fréquence des stimuli cibles (0,5, 1, 2 et 4 kHz). Puis, le démasquage a été évalué en EEG par l’étude 1) des latences précoces (<10 ms, PEA-P), 2) des latences tardives (<50 ms, PEA-T) et 3) de l’onde de discordance (PEA-MMN). Pour ces trois études EEG, l’influence de la cohérence temporelle des bruits bilatéraux a été explorée.Résultats : L’étude perceptive traduit un démasquage croissant lorsque la largeur fréquentielle du bruit controlatéral augmente. L’ajout du bruit controlatéral non corrélé (corrélation=0) se traduit par une amélioration de détection de 1,28 dB, quelle que soit la fréquence des stimuli cibles (antimasquage), alors que l’ajout d’un bruit controlatéral corrélé (corrélation=1) évoque une amélioration de détection lorsque la fréquence des stimuli cibles diminue (démasquage) : 0,97 dB à 4 kHz et 9,25 dB à 0,5 kHz. En PEA-P, les latences des ondes III et V se raccourcissent lorsqu’un bruit controlatéral corrélé ou non corrélé est ajouté (≈0,1 ms). En PEA-T, les amplitudes des ondes P1, N1 et des complexes P1N1 et N1P2 augmentent lorsqu’un bruit controlatéral corrélé ou non corrélé est ajouté. Enfin, l’amplitude de la MMN est plus conséquente lorsque le bruit controlatéral ajouté est corrélé (versus non corrélé). Conclusion : L’étude perceptive explicite l’importance des indices spectraux (antimasquage) et temporels (démasquage), pour améliorer la perception d’un signal initialement masqué. L’étude EEG suggère, quant à elle, un traitement sous-cortical influencé uniquement par les indices spectraux (antimasquage) et un traitement plus cortical influencé par les indices temporels (démasquage). / Background: Binaural unmasking is an essential process for understanding in noisy environments. This mechanism would involve the comparison of time and frequency cues throughout the hearing nerve pathways. However, there is no real consensus evoking a treatment of a binaural masking release at a subcortical and/or a cortical level. The purpose of this study is to investigate the time and frequency cues of the binaural unmasking through a perceptual study, and then through an electroencephalographic study (EEG).Materials and Methods: Normal hearing people were evaluated with a perceptive study to estimate the importance of the binaural unmasking according to 1) the frequency width of the contralateral noise (1 octave, 3 octaves or broadband), 2) the temporal coherence of bilateral noises (correlation equal to 0 or 1) and 3) the frequency of the target stimuli (0.5, 1, 2 and 4 kHz). Binaural unmasking was then evaluated with EEG by studying 1) early latencies (<10 ms, PEA-P), 2) late latencies (<50 ms, PEA-T) and 3), the mismatch wave (PEA- MMN). For these three EEG studies, the influence of the temporal coherence of bilateral noise was investigated.Results: The study shows a growing perceptive binaural unmasking when the frequency width of the contralateral noise increases. The addition of an uncorrelated contralateral noise (correlation = 0) results in a 1.28 dB detection enhancement, regardless of the frequency of the target stimuli (antimasking), while adding a contralateral correlated noise (correlation = 1) refers to a detection enhancement when the frequency of the target stimuli decreases (unmasking): 0.97 dB at 4 kHz and 9.25 dB at 0.5 kHz. The latencies of waves III and V are shortened when a contralateral correlated or uncorrelated noise is added (≈0,1 ms) in the PEA-P. The amplitudes of P1, N1 waves and P1N1 and N1P2 complex increase when contralateral correlated or uncorrelated noise is added in PEA-T. Finally, the amplitude of the MMN is higher when a contralateral correlated noise is added (versus an uncorrelated one).Conclusion: The perceptual study shows the significance of spectral cues (antimasking) and temporal cues (unmasking), to improve the perception of an initially masked signal. The EEG study suggests a subcortical treatment which is only influenced by spectral cues (antimasking) and a cortical processing, influenced by temporal cues (unmasking).

Les mini-granules enrobées offrent un grand potentiel pour la libération contrôlée de médicament par voie orale. Cependant, les mécanismes de libération impliqués ne sont pas toujours élucidés et compris. Ainsi, l’impact de certains paramètres de formulation peut être surprenant. Par exemple, il a été démontré dans ce travail :- La libération du propranolol HCl à partir de mini-granules enrobées avec du Kollicoat SR est plus lente si les mini-granules sont composées de noyaux de sucre comparé à des noyaux de cellulose microcristalline (CMC).Généralement, la tendance inverse est observée, car les noyaux de sucre ont une activité osmotique attirant plus rapidement l’eau à l’intérieur du système et entrainant ainsi, une dissolution et diffusion de la substance active. Ce résultat inattendu est dû à une association de 2 phénomènes : (i) l’effet plastifiant dû au sucre sur le film de Kollicoat SR et (ii) la diminution de la solubilité de cette SA dans le milieu de dissolution en présence de sucre dissous.De plus, le Kollicoat SR 30 D [dispersion aqueuse de poly(vinyl pyrrolidone)] offre des possibilités intéressantes de formulation par sa haute flexibilité et ses propriétés mécaniques stables. En revanche, les mini-granules composées de noyaux de sucre ont tendance à gonfler de par le cumul de l’activité osmotique du noyau et de la SA jusqu’à l’apparition de « cracks », révélés par des images obtenues par micro tomographie à rayons X.- Lorsqu’on augmente la quantité en propranolol HCl dans le système, la cinétique de libération est augmentée, particulièrement avec les mini-granules composées de noyaux de CMC.L’opposé est souvent constaté car accroitre la quantité de SA nécessite un plus grand apport en eau afin de pouvoir tout dissoudre. Les mini-granules à base de CMC présentent probablement des « cracks » malgré un faible gonflement du système, et sont accentués par l’augmentation de la concentration en propranolol HCl.En conclusion, des nouvelles connaissances sur les mécanismes de libération à partir de mini-granules enrobées avec du Kollicoat SR ont été apportées et l’importance du type de SA et la nature du noyau composant le système ont été élucidées.- Dans une deuxième partie, des mini-granules enrobées avec un mélange de polymère (Aquacoat ECD et Eudragit NM 30 D) ont été formulées dans le but de libérer la diprophylline, SA modèle, par diffusion à travers le film de polymère et de pouvoir modéliser sa cinétique à partir de modèles mathématiques. / Polymer coated pellets offer a great potential for control drug delivery system. Nevertheless, the underlying drug release mechanisms can be complex and are not fully understood. Thus, the impact of formulation parameters can be surprising. For example, it has been demonstrated during this thesis that:- The release of propranolol HCl was slower from sugar-based pellets coated with Kollicoat SR compared to microcrystalline cellulose (MCC)-based pellets.Generally, the opposite was observed because the sugar cores are osmotically active attracting more and more water into the system leading to a fast dissolution and diffusion of the drug, especially with high water-soluble drug. This unexpected result is due to a combination of two phenomena: (i) The plasticizing effect of sugar for the film coating and (ii) Decrease in drug solubility in the release medium due to the presence of co-dissolved sugar.In addition, Kollicoat SR 30 D [an aqueous dispersion of poly(vinyl acetate) also containing small amounts of poly(vinyl pyrrolidone) and sodium lauryl sulfate] is a very interesting polymer owing to its high flexibility and stable mechanical properties. However, sugar-based pellets tend to swell by the osmotic pressure created by the high water-soluble API and the sugar until crack formation, clearly visible on the images obtained by X-ray micro tomography.- Propranolol HCl release in phosphate buffer pH 7.4 increases by increasing the drug loading into the system, especially from MCC-based pellets.The opposite was often observed since the amount of water within the drug reservoir might not be sufficient to dissolve all drug. MCC-based pellets likely presented also cracks despite a low swelling of the system, accentuated by the increase of propranolol HCl concentration.To conclude, new insights on the underlying drug release mechanisms from Kollicoat SR coated pellets were provided. The importance of the type of drug and the nature of starter cores were elucidated.- In the second part, diprophylline loaded pellets coated with a polymer blend composed of Aquacoat ECD and Eudragit NM were prepared in order to control the drug release only by diffusion through the intact polymeric film and to predict the drug kinetics using mathematical models.

Carbon monoxide (CO) is an endogenous signaling molecule and has therapeutic values. However, the application of CO in the development of therapeutic options is hampered by the lack of pharmaceutically acceptable delivery methods. Inhalation of CO is not an ideal option for wide-spread clinical applications. Existing CO releasing molecules (CORMs) are mostly metal complexes, which have toxicity concerns to overcome. Some metal free CORMs have been developed. However, they all require light as a trigger to release CO, which limits their applications in vivo. Herein, we describe a metal-free CO prodrug approach using an intramolecular inverse electron-demanded Diels-Alder reaction. Such prodrugs can release CO spontaneously under physiological conditions with tunable release rates with the concomitant formation of a fluorescent reporter after CO releases. This intramolecular “click and release” strategy represents a milestone in the development of CO based therapeutics.

This experimental work investigated the development and testing of a controlled release system for methionine. Methionine is one of the limiting amino acids for the milk production in dairy cows. The quantities of methionine which reach the small intestine are affected by the bacteria in the rumen which utilize methionine. A controlled release system which will offer a protective barrier for methionine may ensure that the methionine reaches the small intestine in sufficient quantities. The work involved the development of a coating around methionine crystals, which would act as a barrier, protecting it from the rumen conditions. Zein and kafirin proteins from maize and sorghum, respectively, were used as the principal coating components for the controlled release system. Two different approaches were used in the development of the controlled release system. First, the zein and kafirin proteins were tested for their ability to act as barriers for the controlled release of methionine, and second, zein and kafirin microparticles were used as the controlled release agents. Relatively successful, laboratory-scale methods were developed for coating the methionine with the proteins and the microparticles. Protein coatings were made by addition of methionine crystals to acid-dissolved proteins which led to the formation of a protein/methionine matrix. For coating the methionine with microparticles, glacial acetic acid was used to fuse microparticles around the methionine crystals. Dissolution assays were performed to test the release of methionine from the coatings under simulated rumen conditions. Both the zein and kafirin and microparticle coatings exhibited a barrier effect for methionine. The barrier effects of these coatings were influenced by several factors. Increasing the proportion of the coating agents led to improved barrier properties. However, this only occurred until a certain proportion of coating agent was present (50%), after which the barrier properties no longer increased. Heat treatment of the coatings also increased the barrier properties of the coatings. This may be due to the formation of disulphide cross-links being formed during the application of heat. When a simple extrusion method was used to form the coatings, the barrier properties also improved in comparison to those coatings which were not formed using extrusion. When producing the microparticles, it was found that only the laboratory extracted kafirin preparation with 85% (db) protein formed microparticles. It was hypothesized that microparticle formation might be related to the purity of the protein preparations. Scanning electron microscopy of the coatings after the dissolution tests and pepsin digestion revealed pores on the surface of the coating. These were probably where the methionine leached from the coating into the dissolution medium. The protein coatings did act as partial barriers, extending the release of methionine. From the release curves of methionine from the coatings, it could be seen that a sustained release of methionine occurred over a period of time, rather than a controlled release of methionine at a certain time. The aim of the application was thus only partially achieved as a complete protective barrier for methionine was not obtained from the protein coatings. No significant difference between the barrier properties of the coatings prepared from the proteins themselves and the microparticles were found. However, when based on equal protein purity the kafirin protein coatings showed the most effective barrier properties. Further research regarding kafirin coatings as a controlled release agent is recommended based on the results of the above named calculation. This research would entail investigating various coating technologies and methods. / Dissertation (MSc)--University of Pretoria, 2011. / Food Science / unrestricted

La perception de la flaveur des aliments dépend de la perception de plusieurs composés en mélange dans des proportions équilibrées. Interactions perceptives entre différents odorants ainsi que la libération dynamique des odorants par la matrice alimentaire sont les principaux facteurs qui influencent la perception globale. L’objectif de cette thèse de doctorat était d’étudier la perception du mélange d’odorants qui constituent l’arôme du fromage à pâte pressée, en prenant en compte les interactions perceptives et la dynamique de libération des composés par la matrice. Une stratégie, comprenant une caractérisation complète des odorants des fromages, suivie d’une recombinaison qualitative et d’une étude détaillée des rôles respectifs des composés clés, et finalement la prise en compte de la dynamique de libération par incorporation des composés dans une matrice fromagère, a été appliquée. Des caractérisations approfondies sensorielles et instrumentales nous ont permis de mettre en évidence des relations entre la perception sensorielle et la composition des composés volatils et proposer des hypothèses. La recombinaison des différents composés a été testée afin d’étudier le rôle de chacun en mélange. Aidés par des apprentis aromaticiens durant la phase des recombinaisons nous avons pu observer particulièrement que 12 composés étaient très importants pour l’odeur du fromage. Par la suite nous avons étudié des interactions entre odeurs en appliquant des techniques de stimulation odorante en phase gazeuse, puis la dynamique de libération des composés en incorporant l’arôme dans une matrice fromagère par des techniques permettant de mesurer la quantité libérée en fonction du temps. / Perception of the aroma of food products depends both the chemical composition of food and human neurophysiology. The perception of food flavour, including cheese often relies on the perception of several aroma compounds in mixture in balanced proportions. Perceptual interactions among aroma compounds in mixtures and also the release of aroma compounds from the food product are the main factors that influence the global perceived aroma of food. Hence, the objective of this PhD study was to investigate the mixture of aroma compounds representing the aroma of semi-hard cheese by taking into account perceptual interactions among odorants and the dynamic release of the compounds by the cheese matrix. A strategy involving a complete characterisation of the cheeses followed by a recombination and investigation of the role of the key-aroma compounds and the dynamic release of the aroma compounds from the cheese matrix was taken into account. Comparison of the sensory and instrumental characteristics was made in order to highlight relationships between sensory perception of the aroma and the volatile composition of the cheeses and thus point out the molecular origins of the perceived cheese aroma. Recombination of selected aroma compounds was tested, in order to study the role of each aroma compound within the mixture. Especially 12 compounds seemed important for the semi-hard cheese aroma. To investigate the odour-odour interactions, different odour-stimulation tools were applied and dynamic release of aroma compounds was taken into account by incorporating the aroma compounds into a cheese matrix by different techniques allowing measuring the quantities released as function of time.

Local anaesthetic drugs are usually administered as symptom relieving drug formulations for the treatment of pain in superficial skin extremities. The anaesthesia is delivered into skin tissues at the site of pain because of nociceptive receptors. Concerns that exist regarding local anaesthetic drug formulations are low drug encapsulation efficiency, polydispersity of colloidal formulations, chemical interactions of released local anaesthetic drug with skin proteins and bulk viscoelastic properties. Complimenting drug formulation characteristics are the desirable rates of controlled release of drug molecules from chosen formulations pertaining to favourable in vitro skin permeation kinetics are imperative pharmaceutics based research areas because skin percutaneous delivery has distinct barrier property restrictions for passive diffusion (PD) of active molecules. Lidocaine is currently the active anaesthetic molecule of choice in local anaesthesia by clinicians because of minimum toxicity and good potency. It is a low molecular weight drug comprising of electron donating and electron withdrawing functional groups with the capacity to interact by hydrogen bonding and electrostatic interactions with several drug formulation vehicles. In this work, a naturally occurring bi-polymeric formulation was achieved with lidocaine NaCMC:gelatine hydrogel. Lidocaine NaCMC:gelatine ratio of 1:2.3 was the most favourable formulation because of faster skin permeation kinetics. Lidocaine NaCMC:gelatine 1:2.7 provided the highest drug encapsulation efficiency. This resulted in high, sustained permeation rates after adaptation of the microneedle (MN) poke and patch technique, past the stratum corneum layer of skin for quick target delivery in attaining a maximum permeation flux of near 6.0 μg/cm2/h in the hypodermis layer. Mass balance of in vitro studies using an indirect approach to quantify lidocaine permeation showed significant lidocaine permeation in skin. Subsequent vertical and horizontal (depth averaged) in vitro studies using similar MN techniques resulted in crossing minimum therapeutic level across a 10 mm radius from the epicentre of the skin sample at major reduced lag times of minutes for vertical permeation and within 0.5 hours for horizontal permeation. Furthermore, the spreadability of lidocaine NaCMC:gelatine hydrogel shows favourability in the control of droplet spreading on MN treated skin.